The calibrated model correctly predicted the optimal anti-TfR affinity required to maximize brain exposure of therapeutic antibodies in the cynomolgus monkey and was scaled to predict the optimal affinity of anti-TfR bispecifics in humans. Thus, this model provides a framework for testing critical ...
Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives are critical for therapeutic programs. Here, we identify 3 mutations (T307P, L309Q, and Q311R or “TLQ”) in the Fc region of human IgG1 which disrupt interaction with protein A while enhancing in...
For treatment of malignant diseases, monoclonal antibodies typically need to be modified to enhance efficacy and to use them in humans. One important modification is the reduction of immunogenicity of rodent monoclonal antibodies by chimerization, humanization throughgrafting of complementarity determining re...
Pianko explains that the recent FDA approvals of the bispecific antibodies teclistamab, elranatamab, and talquetamab and have dramatically impacted RRMM treatment. These new, highly effective immunotherapies provide options for RRMM patients who previously had poor choices after their fifth line of ther...
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing antibodies are a promising therapy. A noncompeting pair of human neutralizing antibodies (B38 and H4) blocking SARS-CoV-2 bindin...
Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin. Cancer Res. 2006;1 ... R.,C.,Grabert - 《Clinical Cancer Research》 被引量: 0发表: 2006年 Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antib...
to the U.S. Food and Drug Administration (FDA) for regulatory review. It also presents a table that lists the bispecific antibodies in clinical development including Ertumaxomab from pharmaceutical company Trion Pharma GmbH.关键词: Humans Antibodies, Bispecific Precursor Cell Lymphoblastic Leukemia-...
Genetic engineering has generally been accepted as a method of choice for the production of clinical grade antibodies for in vivo applications, as this technology provides for structurally controlled molecules that have a small size and can be produced in large quantities. Various strategies are curren...
Administration of therapeutic antibodies in humans may trigger the production of anti-drug antibodies (ADAs), which may have unwanted consequences. ADAs may reduce or abrogate the activity of the antibodies by blocking their function or by removing them from circulation, or they can lead to toxic ...
antibodies with CD137 agonist antibodies in these models synergistically enhances anti-tumor responses19,20,21,22,23. Given the preclinical data, along with the high frequency of PD-1 and CD137 co-expression on tumor-specific CD8+tumor-infiltrating lymphocytes (TILs) found in humans, there is ...